RONALD LEON: Open Payments
NPI 1467418830 · ANTIOCH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$25,563 in 200 payments from 13 companies in 2025. Trend: 2023 $24,481 · 2024 $17,955 · 2025 $25,563
Speaker / faculty: $13,010Consulting: $6,230Food & beverage: $3,999Travel & lodging: $2,158Education: $166
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 44 | $12,378 |
| ABBVIE INC. | 31 | $10,180 |
| Neurocrine BioSciences, Inc. | 28 | $621 |
| Teva Pharmaceuticals USA, Inc. | 15 | $533 |
| E.R. Squibb & Sons, L.L.C. | 16 | $409 |
| Vanda Pharmaceuticals Inc. | 9 | $360 |
| Axsome Therapeutics, Inc. | 17 | $243 |
| Janssen Pharmaceuticals, Inc | 8 | $188 |
| Otsuka America Pharmaceutical, Inc. | 9 | $187 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $180 |
Products named: LYBALVI, VRAYLAR, INGREZZA, COBENFY, ARISTADA, REXULTI, FANAPT, Auvelity.
Industry payments across CA — which companies pay providers there.
